We have determined the DNA sequence of the gyrA gene of the fluoroquinolone-resistant Escherichia coli isolate 205096 (MIC of ciprofloxacin, 128 ,ug/ml), which was recently demonstrated to be a gyrA mutant (P. Heisig and B. Wiedemann, Antimicrob. Agents Chemother. 35:2031-2036, 1991) . Compared with the gyrA+ gene of E. coli K-12, 55 nucleotide changes were found. Three of these resulted in amino acid exchanges: Ser-83--Leu, Asp-87-*Gly, and Asp-678-*Glu. A 0.7-kb DNA fragment containing two of these mutations (Ser-83-*Leu and Asp-87-*Gly) was isolated and fused in frame to the residual 3' coding region of gyrA+ in a plasmid to yield a chimeric gyrA gene (gyrA#). After introduction into E. coli 205096, this gyrA# gene does not increase the fluoroquinolone susceptibility of the resulting heterodiploid strain in a dominance test, while the gyrA' gene does. The ciprofloxacin concentration necessary to inhibit by 90%o (IC90) the supercoiling activity of gyrase isolated from E. coli 205096 is above 2,000 ,ug/mI. An identical result was found for gyrase reconstituted in vitro from the gyrB+ gene product and the chimeric gyrA# gene product. This is more than a 4,000-fold increase compared with the IC90 determined for gyrase from E. coli K-12 (gyrA+) (IC90, 0.5 ,g of ciprofloxacin per ml). No indications for the involvement of the gyrB gene or for alterations in quinolone permeation were found.
High-level resistance to fluoroquinolones (i.e., MIC of ciprofloxacin [CIP] , > 1 ,ug/ml) is rarely found among clinical isolates of Escherichia coli (3) ; only one such resistant strain was isolated in vitro (25) . In two clinical isolates (1, 20) and the one strain isolated in vitro, reduced permeabilities of the outer membranes for quinolones and some unrelated drugs were detected in addition to a lowered sensitivity of DNA gyrase towards quinolones. DNA gyrase is believed to be the primary target for quinolone action. Gyrase consists of two homodimers of subunits A and B and catalyzes ATP-dependent supercoiling of DNA (for a review, see (41) . Two different one-step mutations in the gyrB gene coding for the B subunit of gyrase were detected in E. coli KL16: Asp-426---Asn results in a decrease in the susceptibilities to acidic quinolones but an increase in those to amphoteric quinolones, while Lys-447-->Glu results in a decrease of the susceptibilities to all quinolones (40, 42) . For both gyrA and gyrB mutants, dominance of the respective wild-type allele was demonstrated (13, 22) .
Highly fluoroquinolone-resistant E. coli strains have not yet been examined by DNA sequencing. However, E. coli isolate 205096 (MIC of CIP, 128 ,ug/ml) was characterized genetically by introducing a plasmid-coded gyrA+ gene conferring susceptibility to quinolone (dominance test). The results provided evidence for gyrA mutations to be solely responsible for high-level resistance to fluoroquinolones in this strain (14) .
Thus, the goal of this study was to identify and characterize mutations in the gyrA gene of E. coli 205096.
MATERIALS AND METHODS
Antibiotics. All antibiotics were kindly supplied by the following manufacturers: ampicillin and CIP, Bayer, Leverkusen, Germany; kanamycin, Squibb, Bristol-Myers, Syracuse, N.Y.; nalidixic acid, Sterling-Winthrop, Guildford, United Kingdom.
Strains and plasmids. Highly fluoroquinolone-resistant isolate E. coli 205096 (14) was obtained from C. Krasemann (Bayer AG). E. coli K-12 strains used in this study were DH5a [F-48Od lacZ AM15 A(1acZYA-argF)U169 endAl recAl hsdRl7(rK iK) deoR thi-l supE44 gyrA96 reL41] (Life Technologies, Eggenstein, Germany); JM83 (36); C600SN (14) ; JF703 (ompF [5] ), obtained from B. Bachmann (E. coli Genetic Stock Center); KL16 (13); and (gyrB [17] (23) . The susceptibilities of the transformants to quinolones were determined by the single-cell MIC (scMIC) method of Richmond and Wotton (28), essentially as described previously (14) .
DNA transfer techniques. Plasmid DNA was introduced into all E. coli strains by a transformation procedure described by Maniatis et al. (18) .
Amplification of DNA and subsequent DNA sequence determination. Chromosomal DNA was prepared (2) and subjected to polymerase chain reaction (PCR) by using oligonu- For the determination of the complete DNA sequence of the gyrA gene, the 5' half and the 3' half of the gene were isolated as PCR fragments. One additional mutation, leading to amino acid exchange Asp-678--+Glu, was identified at nt 2034 (C-A). Additionally, 52 silent mutations were identified, which are distributed over the whole coding region (data not shown). One nucleotide exchange was identified in the region upstream of the coding region (G-*A at nt -179).
Genetic characterization of gyrA mutations in a dominance test. To investigate whether the two mutations in the QRDR of the gyrA# gene of pBP514-3 are sufficient to mediate high-level resistance to fluoroquinolones, plasmids pBP514-3 Table 2 . Complete dominance was observed with pBP514 (identical to the data obtained with plasmid pBP515 [14] ), but no effect was detectable with pBP514-3. To exclude any nonspecific effects on the susceptibilities to quinolones of transconjugants because of the presence of a plasmid, plasmid pBP500 was introduced into the strain. Plasmid pBP500 is identical to pBP514 but lacks the gyrA + gene. The presence of pBP500 had no effect on susceptibility. To examine whether gyrB alterations are involved, plasmid pBP547 was introduced into E. coli 205096. Plasmid pBP547 was obtained by inserting the gyrB+ gene of E. coli K-12 on a 3.5-kb BstBI-NruI fragment from plasmid pMK47 into the filled-in BamHI site of pBP500. While transformants of the gyrB mutant KL16nal-31 show scMICs of CIP and nalidixic acid identical to those with KL16, the susceptibilities of neither C600SN
(gyrA) nor E. coli 205096 were altered after introduction of plasmid pBP547 (Table 2 ).
Overexpression and characterization of a chimeric gyrA subunit. The effect of the two mutations on the sensitivity to quinolones of gyrase was examined after cloning the gyrA genes of pBP514 (gyrA+) and pBP514-3 (gyrA ) as 3-kb EcoRI-XbaI fragments into the EcoRI-XbaI sites of plasmid pT7-6 to yield plasmids pBP7614 (gyrA+) and pBP7614-3 (gyrA#), respectively. This places the gyrA genes under the control of the strong, inducible T7+10 promoter on plasmid pT7-6. After transformation of JM83 cells, the plasmids were isolated and characterized by restriction endonuclease cleavage. The presence of the two mutations (Ser-83--+Leu and Asp-87--Gly) in pBP7614-3 was confirmed by determining the DNA sequence. Plasmids pBP7614 and pBP7614-3 were introduced separately into JM83 cells carrying plasmid pGP1-2. Expression of the gyrA genes was induced by shifting the temperature to 42°C followed by the addition of rifampin (35) . Gyrase A subunits were isolated in combination with gyrase B subunits overproduced in a similar system by using plasmid pBP7647. Plasmid pBP7647 contains the gyrB+ gene as a 3.5-kb XbaI-SacI fragment from pBP547 inserted into the XbaI-SacI sites of pT7-6. Gyrase from E. coli 205096 was isolated without heat or rifampin treatment. 56 nt changes were identified. One was located upstream of the structural gene (nt -179), and the remaining 55 were distributed over the coding region. Of these mutations, 52 were silent. Although the pattern of the silent nucleotide changes in the QRDR (Fig. 1) (gyrB+) coded for by the pT7-6 derivative pBP7647. The supercoiling activity of the gyrase containing the chimeric A# subunit is as refractory to CIP as the gyrase of E. coli 205096 (Fig. 2) . Additionally, absence of the third mutation (Asp-678--Glu) in the chimeric gyrA# subunit and replacement of the gyrase B subunit of 205096 by that of E. coli K-12 did not alter the sensitivity of the reconstituted gyrase holoenzyme. These data demonstrate that only two mutations within the QRDR of the gyrase subunit A are responsible for an at least 4,000-fold decrease in the sensitivity to CIP of the gyrase from E. coli 205096. This is in good agreement with the difference of about 4,200 (from 0.015 to 64 ,ug of CIP per ml [ Table 2 ]) in the scMICs determined for strain 205096 (gyrA) and for strain 205096 containing plasmid pBP514 (gyrA+). These data, together with the results of the dominance test with plasmid pBP547 (gyrB+) ( Table 2) argue against the involvement of changes in gyrB in high-level resistance to fluoroquinolones. Finally, no significant differences in CIP accumulation between strain 205096 and a randomly chosen E. coli isolate susceptible to quinolones, tetracycline, and chloramphenicol (data not shown) were detectable, eliminating permeability changes as an additional factor involved in resistance to fluoroquinolones. These are the first data demonstrating that a double mutation in the QRDR of the gyrA gene accounts for high-level resistance to fluoroquinolones in a clinical isolate of E. coli.
Several attempts made by others (8, 29, 38) failed to isolate in vitro highly fluoroquinolone-resistant E. coli mutants. Thus, it is tempting to speculate whether additional mutations, which do not affect the susceptibility to quinolones of gyrase, are required to obtain highly fluoroquinoloneresistant E. coli mutants or whether the presence of the Ser-83---Leu mutation is required to stabilize an Asp-87-*Gly mutation.
Both Ser-83 and Asp-87 are located in the QRDR ofgyrA. This region of the E. coli enzyme (34) , which is highly homologous to those of S. aureus (15, 31) , Staphylococcus epidermidis (32), Kiebsiella pneumoniae (7), and B. subtilis (21) , is a compact domain responsible for enzymatic breakage and reunion of DNA (24, 27) . The mutations are in close vicinity to the Tyr-122 residue, which interacts covalently with DNA during the enzymatic action of gyrase (16) . Thus, on the one hand, the accessibility of a putative quinolonebinding site in the gyrase-DNA complex might be reduced (24) . On the other hand, the two mutations might interfere with normal enzyme function. We have no indications from the data of the supercoiling test for the latter possibility. Moreover, the doubling time of strain 205096 cells is comparable to that of wild-type E. coli (data not shown).
Thus, resolution of the molecular structure of the gyrase-DNA complex and identification of the sites of interaction of this complex with quinolone molecules are required to elucidate the mode of action of the quinolones. This might help investigation of the effect of single and double mutations in the gyrase A subunit at the molecular level.
VgyrA MUTATIONS IN FLUOROQUINOLONE-RESISTANT E. COLI fluoroquinolones (24)-comparison of the complete coding regions revealed that only 21 of the 55 mutations are identical to those found for strain 227 (6) .
Three of the 55 mutations in gyrA (strain 205096) resulted in amino acid exchanges: Ser-83--Leu, Asp-87---Gly, and Asp-678--Glu. The latter was also detected in strain 227, but has been shown not to be involved in quinolone resistance (6); it is located in a less-conserved region ofgyrA (39) . For Bacillus subtilis, a Glu residue is found at nt 678 (21) .
Alterations of Ser-83 are most frequently found among clinical isolates of E. coli (9) . These mutations are responsible for low-level resistance to fluoroquinolones (i.e., MIC of CIP, < 1 ,ug/ml) in both laboratory mutants and clinical isolates of E. coli (6, 9, 24, 43) . A Ser-83-*Leu mutation results in an increase in the MIC of CIP from 0.013 to 0. 25 ,ug/ml (factor 20) (43) . In Staphylococcus aureus, the alteration of the corresponding Ser-84 residue (Ser-84--3Leu) is to some unknown degree associated with the development of high-level resistance to fluoroquinolones (i.e., MIC of CIP, >1 ,ug/ml) in paired clinical isolates (31) . However, considering a MIC of 0.5 ,ug of CIP per ml for susceptible wild-type S. aureus strains, it is not unusual to isolate point mutations requiring MICs exceeding 1 ,g/ml.
The Asp-87--Gly mutation is a novel mutation leading to the loss of a negatively charged residue in the QRDR of the gyrase A protein. In this respect, it resembles the Asp-87-Val mutation found in a clinical isolate ofE. coli (24) and an Asp-87-->Thr mutation identified in a one-step mutant of E. coli K-12 JM83 selected in vitro (13a 2 . Determination of the CIP sensitivities for the different gyrases. Supercoiling reactions were performed as described in the text by using comparable activities of gyrase (1 U). Wild-type gyrase consisted of subunits A' and B+ overexpressed by using plasmids pBP7614 (gyrA+) and pBP7647 (gyrB+). Gyrase prepared from E. coli 205096 consisted of the original A and B subunits of the isolate. Chimeric gyrase consisted of A# and B+ subunits overexpressed by using plasmids pBP7614-3 (gyrA#) and pBP7647 (gyrB+). The CIP concentration used in each reaction is given above the lanes in micrograms per milliliter. In the last two lanes of each assay, plasmid pBR322 is shown in the relaxed (rel) and supercoiled (sc) forms. The electrophoretic mobilities of the supercoiled, linear (lin), and the open circular (oc) forms of pBR322 are indicated. The diffuse fluorescent bands of low mobility (A#B+ and AB) are due to CIP, which was used in high concentrations (2 1,000 ,ug/ml) in these assays. At CIP concentrations above 2,000 ,ug/ml, formation of a precipitate interfered with gyrase activity. VOL. 37 
